Chinese
NOVEMBER 12, 2020
Pfizer CEO Albert Bourla sold $5.6 million of his stock in the US pharmaceutical company on the same day it announced promising results for its Covid-19 vaccine candidate, Wednesday filings have showed.
The company, however, has reportedly said the sale was part of a pre-arranged periodic divestment plan when the stock reaches a certain price.
AFP reports that a disclosure with US market regulator SEC, Bourla sold 132,508 shares at $41.94 each on Monday.
Read also: First COVID-19 Vaccine Is 90 Percent Effective, Says Pfizer
An executive vice president at the company, Sally Susman, also sold around $1.8 million in stock, or 43,662 shares.
Pfizer shares rose by more than seven per cent after peaking at over 15 per cent on Monday, when the drugmaker announced that trials so far had shown its vaccine candidate being developed with German company BioNTech was 90 per cent effective.
The company had not responded to a request for a comment from AFP, but a spokesman quoted by CNN described the sales as prearranged.
Sales at that price were previously scheduled as part of their personal financial management, the company said.
Such plans are designed to shield executives from insider trading accusations.
The Independent National Electoral Commission (INEC) on Sunday criticized the Peoples Democratic Party (PDP) governors…
Two men have been killed in Kwale, Ndokwa West Local Government Area of Delta State,…
Six men connected to Juventus and France midfielder Paul Pogba are set to stand trial…